Rituximab as prophylaxis in chronic relapsing thrombotic thrombocytopenic purpura: A case report and review of the literature

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 4, 2012, Pages 338-341

  Montoya, Roberto C ^a   Poiesz, Bernard J ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

prophylactic; rituximab; thrombotic thrombocytopenic purpura

Indexed keywords

CORTICOSTEROID; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; CASE REPORT; CHRONIC DISEASE; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; FEMALE; HERPES VARICELLA ZOSTER MYELITIS; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MYELITIS; PARESTHESIA; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; REVIEW; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE;

EID: 84861099087     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283529184     Document Type: Review

References (12)

1. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594.
2. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001;98:1765-1772.
3. Vesely SK, Georg JN, Lammle B, Alberio L, El-HarakeF ML. Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-68.
4. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, et al. Prognostic values of anti ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood 2007;109:2815-2822.
5. Sadler JE. von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008;112:11-18.
6. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS13. Br J Haematol 2007;136:451-461.
7. Jasti S, Coyle T, Gentile T, Rosales L, Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher 2008;23:151-156.
8. Schleinitz N, Ebbo M, Mazodier K, Poullin K, Bernit E, Veit V, et al. Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor. Am J Hematol 2007;82:417-418.
9. Galbusera M, Bresin E, Noris M, Gastoldi S, Belotti D, Capoferri C, et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005;106:925-928.
10. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005;106:1932-1937.
11. Benetatos L, Vassou A, Bourants KL. Effectiveness of rituximab as prophylasis in thrombotic thrombocytopenic purpura. Clin Lab Haem 2006;28:288-289.
12. Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, et al. Rituximab as preemptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 2009;101:233-238.